Latest / Pharmacy Podcast Network / Cracking the Concentration: PBMs, Power, and the Fight for Fairness | PBM Reform Podcast
Transcript
- 0:00Speaker 1: This is Greg Raibold and you're listening to the PBM
- 0:02Speaker 1: Reform Podcast.
- 0:09Speaker 2: You are listening to the global network of podcasters dedicated
- 0:12Speaker 2: to the pharmacy profession. Welcome to the Pharmacy podcast Network.
- 0:36Speaker 3: Welcome to the PBM Reform Podcast, where we dive deep
- 0:40Speaker 3: into the world of pharmaceutical benefit management, cutting through the
- 0:44Speaker 3: noise to uncover the truth. Since twenty nineteen, we've been
- 0:49Speaker 3: your go to source for the latest on how PBMs
- 0:52Speaker 3: impact patient care, drug pricing, and the very future of pharmacy.
- 0:57Speaker 3: Here we champion the role of pharmacists.
- 1:00Speaker 4: It's the most knowledgeable advocates for medication safety and expertise.
- 1:05Speaker 4: Join us as we expose and generate discussions that are
- 1:08Speaker 4: reshaping healthcare and explore how we build a better payment
- 1:12Speaker 4: system which focuses on advancing pharmacy care.
- 1:22Speaker 5: Hey, what a special episode of the PBM Reform Podcast.
- 1:27Speaker 5: I am proud to introduce our new host, Greg Rivaled
- 1:31Speaker 5: with APCI. Greg, we've been working on this relaunch of
- 1:36Speaker 5: the PBM Reform Podcast for quite some time.
- 1:39Speaker 2: NICs.
- 1:39Speaker 5: We excited to have you here, so take it away.
- 1:42Speaker 1: Greg. Yeah, thank you so much, appreciate it. You really
- 1:45Speaker 1: excited to be here. Obviously big fan of Pharmacy Podcast
- 1:49Speaker 1: Network and Todd's work for a long time, and so
- 1:52Speaker 1: you know, had the sort of opportunity to be a
- 1:56Speaker 1: guest from time to time and really excited to host,
- 1:58Speaker 1: and could not be more excited. So our first guest
- 2:01Speaker 1: is Ema Freer with American Economic Liberties Project. And look,
- 2:05Speaker 1: it is twenty twenty five. It has been a massive
- 2:09Speaker 1: year for PBM reform at the state level, I would
- 2:11Speaker 1: say the last two to three years, at the federal level,
- 2:15Speaker 1: certainly twenty twenty four and moving into twenty twenty five,
- 2:18Speaker 1: we're seeing all sorts of interesting, interesting things and excited
- 2:22Speaker 1: to talk to Emma because American Economic Liberty Project is
- 2:26Speaker 1: frankly doing some of the most interesting, smartest, and aggressive
- 2:31Speaker 1: work in the PBM space. And importantly, you know, so
- 2:35Speaker 1: much of what we do in pharmacy is unfortunately talking
- 2:39Speaker 1: to echo chambers sometimes right, Sometimes we're talking to ourselves,
- 2:42Speaker 1: We're hearing from ourselves, we're hearing from pharmacists and people
- 2:46Speaker 1: who work exclusively in pharmacy, and American Economic Liberty Project
- 2:50Speaker 1: presents a very very different point of view in that regard,
- 2:53Speaker 1: and so I think it's so important to hear a
- 2:56Speaker 1: some of the smartest voices in the space, and me
- 2:58Speaker 1: also from time to time folks who are not necessarily
- 3:01Speaker 1: pharmacists themselves or representing pharmacy. And so, Emma, thank you
- 3:07Speaker 1: so so much for joining and could be more excited
- 3:09Speaker 1: to have you as sort of our first guests for
- 3:12Speaker 1: the podcast relaunch. Maybe little background about yourself and American
- 3:17Speaker 1: economic liberties.
- 3:20Speaker 2: Yeah, well, thank you so much for having me. It's
- 3:22Speaker 2: a real honor to be the first guest on the
- 3:25Speaker 2: relaunch and a non pharmacist guest. But I've learned so
- 3:30Speaker 2: much working with barmacists and I really appreciate their expertise. Yeah,
- 3:36Speaker 2: a little bit about me and economic liberties. I am
- 3:40Speaker 2: a senior policy analyst for Healthcare AELP and Economic Liberties are.
- 3:46Speaker 2: ALP was founded in twenty twenty. It's a non partisan,
- 3:50Speaker 2: nonprofit research and advocacy organization and it's really focused on
- 3:56Speaker 2: understanding and solving the problem of concentrated atomic power in
- 4:01Speaker 2: the United States. And you kind of alluded to this.
- 4:04Speaker 2: You know, this is a problem across industries. We aren't
- 4:08Speaker 2: only focused in the healthcare space, but as a healthcare
- 4:11Speaker 2: policy analyst, you know, I'm biased and I think that
- 4:14Speaker 2: this problem of concentrated economic power is you know, perhaps
- 4:18Speaker 2: the most dangerous and fatal in the healthcare space and
- 4:21Speaker 2: really deserves our attention. So that's that's a little bit
- 4:25Speaker 2: about our organization and what we do.
- 4:28Speaker 1: Yeah, And what I would say is I love that
- 4:31Speaker 1: point you just made, right, because obviously, you know, consolidated power,
- 4:34Speaker 1: vertical integration, anti competitive conduct is a problem across industries.
- 4:40Speaker 1: Like there's there's no doubt about it, right, and there's
- 4:43Speaker 1: important implications, whether it's in social media, but when you're
- 4:46Speaker 1: talking about healthcare, you're talking about people's lives potentially, and
- 4:51Speaker 1: you know, from my perspective, it just so happens that
- 4:54Speaker 1: when you're talking about vertical integration and PBMs and health
- 4:57Speaker 1: insurance companies in particular, they're amongst the biggest companies in
- 5:01Speaker 1: the world, right, Like this is the massive market share.
- 5:06Speaker 2: Yeah, I think that's something that people don't always realize.
- 5:10Speaker 2: We recently launched this initiative called break Up Big Medicine
- 5:14Speaker 2: that is kind of a home for healthcare work. And
- 5:16Speaker 2: you know, when we talk about big medicine, we're talking
- 5:19Speaker 2: about these vertically integrated healthcare conglomerates. And like an interesting
- 5:24Speaker 2: fact I think, I mean, it's a horrifying fact. But
- 5:27Speaker 2: in two thousand, there were no big healthcare conglomerates on
- 5:31Speaker 2: the Fortune twenty and today there's seven, and so you
- 5:37Speaker 2: just you can see how much bigger and financialized these
- 5:42Speaker 2: companies have become and how powerful they are, you know,
- 5:46Speaker 2: in the economy and the business landscape. And they're making
- 5:51Speaker 2: money off of people's inability to access quality healthcare. So yeah,
- 5:58Speaker 2: I think it's a huge problem and getting more extreme
- 6:03Speaker 2: every year.
- 6:04Speaker 1: Yeah, absolutely, And I want to jump into I think
- 6:07Speaker 1: to start out some of the action from the administration
- 6:11Speaker 1: the second term and also first term. But before that,
- 6:14Speaker 1: can you share just a little bit, Like you have
- 6:16Speaker 1: a pretty good team behind you, right, Like you got
- 6:19Speaker 1: some economists, some folks with pharmacy perspective, like a lot
- 6:24Speaker 1: of different Like like just a little bit maybe about
- 6:27Speaker 1: the team that makes up American economic liberties.
- 6:33Speaker 2: Yeah, we are. We are growing recently, so our team
- 6:35Speaker 2: is getting a little bit bigger in the last few
- 6:37Speaker 2: weeks e've been. But we have an excellent senior fellow
- 6:41Speaker 2: who's a climent sourch named named Benjamin Jolly, who I
- 6:44Speaker 2: have sent Flinda is like a celebrity.
- 6:46Speaker 1: Among so do awesome works.
- 6:50Speaker 2: We have another senior fellow named Hayden Roclay who is
- 6:54Speaker 2: a lawyer and health policy expert. He's doing really interesting
- 6:59Speaker 2: research in to gout to cointegration, especially in the medical
- 7:02Speaker 2: advantage space. We have a whole team of policy analysts, lawyers,
- 7:11Speaker 2: some people with economics degrees. I think we interestingly have
- 7:17Speaker 2: a lot of different background. Some people have polishy economics background.
- 7:21Speaker 2: My background is actually in journalism and I started writing
- 7:24Speaker 2: about health policy and that's how I got into this work.
- 7:27Speaker 2: So I think we have, you know, a kind of
- 7:30Speaker 2: diversity of perspectives that's that's helpful for the work that
- 7:34Speaker 2: we do.
- 7:35Speaker 1: Okay, awesome, Well again, I want to start out with
- 7:38Speaker 1: the administration, but hopefully we can cover some ground because
- 7:42Speaker 1: in a lot of ways, you guys have been a
- 7:44Speaker 1: prominent voice and been willing to be aggressive and look
- 7:48Speaker 1: for sort of comprehensive solutions where I would say a
- 7:50Speaker 1: lot of others in the in the space in the
- 7:52Speaker 1: space can can sometimes be you know, some of the
- 7:55Speaker 1: solutions can feel stale or feel anemic. But but what
- 7:59Speaker 1: the work that you guys are doing and the policies
- 8:01Speaker 1: you're proposing, I think I think are pretty neat, and
- 8:04Speaker 1: so let's let's if you are you comfortable kind of
- 8:06Speaker 1: starting with the administration and the recent executive order.
- 8:09Speaker 2: Yeah, definitely, And that's really nice to hear that APCI.
- 8:13Speaker 2: You know, we have a vote of confidence there. But
- 8:16Speaker 2: we're really focused on, you know, we tackle these problems
- 8:21Speaker 2: from our market perspective, and so we want to restructure
- 8:24Speaker 2: markets to be competitive and there, and so we don't
- 8:28Speaker 2: want incremental changes that are going to allow the market
- 8:32Speaker 2: to continue to function or you know, dysfunction and continue
- 8:37Speaker 2: to hurt competitors and market participants. We want to restructure
- 8:41Speaker 2: markets to be healthy and there.
- 8:44Speaker 1: I love that point. And would you agree that when
- 8:47Speaker 1: you look at the size of these PBMs and insurance
- 8:50Speaker 1: and the vertical integration that you know, in certain ways
- 8:55Speaker 1: incremental where modest changes aren't going to stop the behavior
- 8:59Speaker 1: right there, they're so large and they can slay markets
- 9:03Speaker 1: in such a way that you really do need oftentimes,
- 9:06Speaker 1: you know, meaningful material reform.
- 9:10Speaker 2: Absolutely. Yeah, I think, you know, it's just too far
- 9:13Speaker 2: gone at this point. And we've seen policymakers make incremental
- 9:18Speaker 2: changes for a long time, and I don't think anyone
- 9:22Speaker 2: feels like our drug pricing system or our healthcare system
- 9:25Speaker 2: is operating well. So I think it's time to make
- 9:32Speaker 2: take those biggest swings. And I think we're seeing some
- 9:34Speaker 2: of that momentum build which is really exciting. You know,
- 9:39Speaker 2: the Arkansas LA. I don't want to get off the
- 9:40Speaker 2: topic of what administration has done, but I think we
- 9:43Speaker 2: are seeing some progress there which is really exciting.
- 9:47Speaker 1: Yes, agreed, And so you know, talking about big swings.
- 9:50Speaker 1: I think this is interesting because when Trump did his
- 9:52Speaker 1: latest executive order, I would say focused largely on most
- 9:56Speaker 1: Favored Nation pricing, sort of a fascinating document for a
- 10:01Speaker 1: couple of reasons. One is certainly was a big swing, right, Like,
- 10:05Speaker 1: it wasn't like a modest attempt at bringing down drug prices.
- 10:09Speaker 1: And I also think in certain ways right the intent
- 10:12Speaker 1: was was really good, which is a low range prescription
- 10:14Speaker 1: drug prices for patients at the pharmacy counter. There was
- 10:18Speaker 1: a lot of I think folks sort of trying to
- 10:20Speaker 1: figure out what the implications are, what it meant, and
- 10:22Speaker 1: there still are some really smart people trying to do that.
- 10:26Speaker 1: You all came out of the gate, I would say,
- 10:28Speaker 1: maybe faster than anyone, certainly with like you had a
- 10:31Speaker 1: really prominent op ad that I thought was really well
- 10:34Speaker 1: written and took a strong stance, and just if you'd
- 10:38Speaker 1: be willing to just kind of share what that stance
- 10:41Speaker 1: was on the Executive Order.
- 10:44Speaker 2: Yeah, definitely. So I agree, like it's good that and
- 10:50Speaker 2: we've seen from the first comp administration that he did
- 10:53Speaker 2: take some big swings that I get a drug pricing,
- 10:55Speaker 2: So like that's good that were in the world they're
- 10:59Speaker 2: making big thing is And you know, we absolutely agree
- 11:02Speaker 2: with the administration that drugs are way too expensive in
- 11:06Speaker 2: the US. This is a uniquely American problem and we
- 11:08Speaker 2: need to fix it. You know, in our bed we
- 11:11Speaker 2: really leigh out our concerns, which is that kind of
- 11:17Speaker 2: twofold one. We think that the most Favorite Nation's policy
- 11:21Speaker 2: is kind of based on the long premise and even
- 11:25Speaker 2: if it does take effect, which there's a lot of
- 11:29Speaker 2: uncertainty around, that, it won't actually address the root causes
- 11:34Speaker 2: why drugs are so expensive in the US. And so
- 11:38Speaker 2: this idea that we need the most Favored Nations policy
- 11:41Speaker 2: to force big farm our manufacturers to the Executive Order
- 11:48Speaker 2: basically makes this argument that the reason drug types in
- 11:51Speaker 2: the US are so much higher here than in other
- 11:53Speaker 2: countries is because American patients are subsidizing pharmaceutical manufacturers global
- 12:02Speaker 2: research and development budgets. And there's lots of good research
- 12:05Speaker 2: by other organization that shows that's actually not true. That
- 12:10Speaker 2: pharmaceutical manufacturers often say that they have to charge these
- 12:13Speaker 2: high prices to invest in research and development, and instead
- 12:17Speaker 2: they're using them to jack up executive pay, to engage
- 12:20Speaker 2: in stock buybacks, to do all of these really self
- 12:23Speaker 2: serving behaviors. And actually the reason, you know, for our
- 12:29Speaker 2: organization why drug prices are so high in the US
- 12:32Speaker 2: is because we have chosen in our policy decisions to
- 12:38Speaker 2: subsidize corporate monopolies. So we allow big pharma companies to
- 12:42Speaker 2: completely exploit the patent system to prevent genetic and biosimilar,
- 12:48Speaker 2: more portable options from entering the market. That keeps prices,
- 12:51Speaker 2: you know, much higher than they need to be. And
- 12:55Speaker 2: we also, unlike every other high income country in the world,
- 13:03Speaker 2: have allowed PVMs to play the enormous role in the
- 13:06Speaker 2: setting of drug prices. And you know, in the up
- 13:09Speaker 2: ED we say that high drug prices in the US
- 13:13Speaker 2: is a homegoing problem. We can't make other countries solve
- 13:15Speaker 2: this problem for us by imposing most David nation's policy policies,
- 13:20Speaker 2: and there's a lot like I really want to stress that,
- 13:23Speaker 2: like that policy isn't going to fix the problem, and
- 13:27Speaker 2: also it probably won't be implementable for a lot of reasons.
- 13:30Speaker 2: But we need to solve the reasons at home for
- 13:34Speaker 2: why we have much higher drug prices and in other countries.
- 13:38Speaker 1: Would it be fair to catch it? And obviously this
- 13:41Speaker 1: is simplification, right, but it seems to me that your
- 13:44Speaker 1: position is really that Americans aren't subsidizing lower costs overseas,
- 13:51Speaker 1: they're subsidizing high large GBM profits and insured profits. Is
- 13:56Speaker 1: that fair to exactly?
- 13:59Speaker 2: Yeah, that's how much the sainct read. But yeah, we
- 14:02Speaker 2: are subsidizing something. It's not lower prices abroad. It's got
- 14:07Speaker 2: high topic from these big medicine corporations.
- 14:10Speaker 1: And so I thought to me, sort of interesting, right,
- 14:13Speaker 1: almost like a tale of two cities, because I agree.
- 14:16Speaker 1: I think ultimately PBMs are the primary driver of high
- 14:20Speaker 1: drug prices in the United States. I think obviously even
- 14:22Speaker 1: as first executive order this term, you know, he sort
- 14:26Speaker 1: of honed in on promise, even Enters to some degree
- 14:29Speaker 1: as well as in public public facing comments has made
- 14:33Speaker 1: reference to PBMs. But what I will say, and I
- 14:36Speaker 1: was encouraged by this executive order from the perspective of
- 14:39Speaker 1: at a time where sometimes a lot of the congressional
- 14:44Speaker 1: solutions that have consolidated the most support are really sort
- 14:49Speaker 1: of small step. You've got a president here who is
- 14:53Speaker 1: swinging big and looking to use. When you read through
- 14:57Speaker 1: that executive order, it's fascinating because really it calls on
- 15:02Speaker 1: almost like so many significant agency heads right like it
- 15:05Speaker 1: covered agencies. It calls on HHS, It calls on the FDA,
- 15:09Speaker 1: It calls on the FDC and the DOJ, It calls
- 15:12Speaker 1: on the Secretary of Commerce, all of them to sort
- 15:15Speaker 1: of leverage the goal of lower drug prices. Again, this
- 15:19Speaker 1: is looking from a lens of most favored nations. You
- 15:22Speaker 1: and I have talked about this, I think in the past,
- 15:24Speaker 1: But in his first term he had another executive order
- 15:27Speaker 1: that looked to lower drug prices, and that was dealing
- 15:30Speaker 1: with the Safe Harbor for Pharmaceutical rebates to PBMs.
- 15:36Speaker 2: Yeah, and that's one of that Actually, well, what did
- 15:40Speaker 2: you expand of that? And we would really like to
- 15:43Speaker 2: see the administration that I wilemaking around that. You know,
- 15:47Speaker 2: that rule was finalized at the very end of the
- 15:50Speaker 2: first Tump administration, and then there a series of unrelated
- 15:53Speaker 2: congressional budget rathers has basically been delayed from being implemented
- 15:57Speaker 2: until twenty thirty two, but you know, entirely.
- 16:00Speaker 1: Inflation Reduction Act, right, it was like bumped it to
- 16:02Speaker 1: around twenty thirty two.
- 16:05Speaker 2: Yeah. I think there were a couple of other bills,
- 16:06Speaker 2: but like that was the big one. There was a
- 16:08Speaker 2: big one. Yeah. But you know, that's a great example
- 16:12Speaker 2: of something that would really change the business model of PBMs.
- 16:17Speaker 2: It wouldn't allow them to use these kickbacks that would
- 16:20Speaker 2: otherwise be a felony offense. And are so many other
- 16:24Speaker 2: people and businesses and now the industry. They had this
- 16:28Speaker 2: exemption that's allowing the entire business model to work on
- 16:31Speaker 2: rebased and kickbacks and other discounts that really distort incentives absolutely.
- 16:38Speaker 1: And you know, one of the things that to me
- 16:40Speaker 1: is always interesting is that that sort of the implementation
- 16:43Speaker 1: got delayed and delayed based on a CBO score, And
- 16:47Speaker 1: the CBO score essentially said, hey, this is this is
- 16:49Speaker 1: going to cost the federal government money. It based it
- 16:52Speaker 1: on really a projection seemingly pulled out of air. I
- 16:57Speaker 1: think it said based on stakeholder input that fifteen percent
- 17:00Speaker 1: less rebates would be negotiated. But what it was a
- 17:04Speaker 1: footnote in the CBO score without a number. But if
- 17:08Speaker 1: you read the footnote and you trace it to the
- 17:10Speaker 1: Medicare Actuary report, I think it was like ninety three
- 17:13Speaker 1: billion in savings at the drug counter for patients by
- 17:17Speaker 1: implementing that.
- 17:17Speaker 2: Right.
- 17:18Speaker 1: Ultimately, what we're talking about here is PBMs are demanding
- 17:22Speaker 1: high or demanding negotion, whatever the word is for formula replacement.
- 17:26Speaker 1: They are demanding from drug manufacturers massive rebates. But they're
- 17:31Speaker 1: basically basing beneficiary cost sharing out of pocket costs based
- 17:36Speaker 1: on gross prices and not net prices. And that essentially
- 17:40Speaker 1: what Trump sought to do in that first term was
- 17:42Speaker 1: return those savings to the patients themselves instead of allowing
- 17:46Speaker 1: the PBMs and the insurers to keep it. Would you
- 17:49Speaker 1: all like to see Trump revisit that and Congress, Yeah, no,
- 17:54Speaker 1: we definitely would.
- 17:55Speaker 2: And you know, we have a lot of the same
- 17:57Speaker 2: concerns with the CBO scoring, lot assumptions that have really
- 18:02Speaker 2: sign made what we think will be a very effective
- 18:06Speaker 2: policy and invention. We would like to see a success
- 18:09Speaker 2: make that change. We would also like to see Congress
- 18:11Speaker 2: pass legislation to you know, codify the repeal of the
- 18:16Speaker 2: safe Harbor. And you don't have to take my word
- 18:20Speaker 2: for why we think it will be effective. There's lots
- 18:24Speaker 2: of good reporting from states that have carged PBMs out
- 18:28Speaker 2: of their state Medicaid managed care programs, and you see
- 18:32Speaker 2: how much money they're saving by getting rid of PBMs
- 18:35Speaker 2: in this rebate based system. I'm from Cleveland, so I'll
- 18:38Speaker 2: brag on Ohio, which just released a report that shows
- 18:42Speaker 2: that the state's Medicaid programs saved more than three hundred
- 18:46Speaker 2: and thirty million dollars in just two years by cutting
- 18:49Speaker 2: out the big big PBMs from its program, and they
- 18:53Speaker 2: were able to reinvest more than half of that into
- 18:56Speaker 2: you know, really significantly increasing BUMA cvmbursement rate. So this
- 19:00Speaker 2: idea that like, you can't increase pharmacy V embursement and
- 19:04Speaker 2: save money. PBMs are taking so much money out of
- 19:07Speaker 2: the system. There's a lot of room to improve pharmacy
- 19:11Speaker 2: V embursement, get rid of pbm gript save patients money,
- 19:16Speaker 2: shave tax payers money. Like we are seeing this IMPACTICE
- 19:20Speaker 2: at the shape level.
- 19:22Speaker 1: Yeah, And well I don't I don't think anybody says
- 19:25Speaker 1: said it better than that, and love that you point
- 19:26Speaker 1: out Ohio, you know, particularly with medicaid, Ohio has led
- 19:30Speaker 1: the way and they're doing some interesting things now in
- 19:32Speaker 1: their legislative session. But obviously, you know, good friend of
- 19:36Speaker 1: and fan of Antonio Chaccha and three Access and the
- 19:39Speaker 1: work that they have done and really sort of the
- 19:42Speaker 1: originals in exposing PBM spread pricing games and the money
- 19:47Speaker 1: that they can suck out of the system, you know,
- 19:49Speaker 1: when you have these governmental payers, and of course we
- 19:51Speaker 1: know that there's similar games, you know, in the commercial
- 19:55Speaker 1: market as well. Okay, so so fan of Trump's initial
- 20:00Speaker 1: you know, initial first term efforts with regard to repealing
- 20:03Speaker 1: the rebate safe harbor as to drug manufacture payments of PBMs,
- 20:07Speaker 1: you guys also weighed in a really smart way recently,
- 20:11Speaker 1: I think in connection with and I thought this was
- 20:13Speaker 1: particularly interesting. You know, the DOJ has formed a test
- 20:17Speaker 1: force I think it's an anti competitive regulation task force,
- 20:21Speaker 1: and they were submitting public comments and I'll tell you
- 20:25Speaker 1: one of the things that I was thrilled to see
- 20:28Speaker 1: out of the gate was that they referenced regulatory capture,
- 20:32Speaker 1: right because it's something that I don't think gets talked
- 20:34Speaker 1: about enough. The control that you know, large companies, particularly
- 20:38Speaker 1: in the healthcare space, insurers and PBMs can have over
- 20:42Speaker 1: parts of agencies that are really supposed to be overseeing
- 20:45Speaker 1: them in many ways, and yet they're able to shape policies, rules,
- 20:51Speaker 1: regulations in a manner that so often really opens the
- 20:55Speaker 1: door for some of the bad practices or anti competitive
- 20:58Speaker 1: practices that they engage in. But you all submitted really
- 21:02Speaker 1: really smart comments on it. I'd like to talk a
- 21:04Speaker 1: little bit about it because you all, again you're not
- 21:06Speaker 1: I mean, I know you in particular are focused on healthcare,
- 21:09Speaker 1: but American Economic liberties itself is not just focused on healthcare, right,
- 21:13Speaker 1: and there's there's so many areas that could focus on,
- 21:17Speaker 1: but a portion of your comments did focus on in
- 21:20Speaker 1: healthcare in particular with regard to pharmacy benefit managers. So
- 21:26Speaker 1: just love to hear your thoughts a little bit about
- 21:29Speaker 1: how that came together and what you submitted.
- 21:32Speaker 2: Yeah, definitely. So, like you said, the Justice Department has
- 21:37Speaker 2: this new Anti Competitive Regulations task Force, and we put
- 21:42Speaker 2: together healthcare specific comments, and you know, we don't believe
- 21:47Speaker 2: that deregulation alone is a sufficient solution to this problem
- 21:52Speaker 2: of you know, increasingly concentrated economic power, and you know,
- 21:57Speaker 2: in a lot of cases, increase regulation of healthcare gets
- 22:00Speaker 2: it's necessary to protect patients and payers. But given this
- 22:04Speaker 2: request for information, this opportunity to comment, we really wanted
- 22:08Speaker 2: to point out policies that could either be repealed, like
- 22:13Speaker 2: the shape hire work for prebms, or revised to get
- 22:17Speaker 2: rid of some of that we often refer to an
- 22:22Speaker 2: ALP as like private regulation by private corporations. They're acting
- 22:28Speaker 2: that's kind of their own governments and it's hurting the
- 22:31Speaker 2: rest of us. So we wanted to identify some of
- 22:35Speaker 2: those policies that we see as really harmful and that
- 22:38Speaker 2: would be you know, ripe for deregulation, and then also
- 22:43Speaker 2: emphasize that deregulation must happen in the context of strengthening
- 22:49Speaker 2: pro competitive regulations. So we really see that as increasing
- 22:54Speaker 2: enforcement of anti trust laws, and all of the important
- 22:57Speaker 2: work that the federal government does is to you know,
- 23:01Speaker 2: it's not just getting rid of anti competitive regulations, it's
- 23:04Speaker 2: also reinforcing pro competitive regulation.
- 23:08Speaker 1: Just what's sah? Yeah, I thought I thought that was
- 23:10Speaker 1: really well done. I also liked that you guys referenced
- 23:13Speaker 1: the non interference clause with regard to medicare. I thought
- 23:16Speaker 1: that was a really good, smart take. It's smart call out.
- 23:21Speaker 2: I think that's, you know, a good example of something
- 23:23Speaker 2: that really prohibits hhs from fully addressing abuse of PBM
- 23:29Speaker 2: practices like low cost reimbursements, and we want to empower
- 23:33Speaker 2: federal agencies to do their job to regulate these markets.
- 23:39Speaker 1: Yeah, yeah, absolutely, And again the PBMs and insurres have
- 23:43Speaker 1: been really successful in pushing back against hhscms and saying
- 23:49Speaker 1: basically getting CMS to agree with their interpretation of the
- 23:53Speaker 1: non interference clause so that they in no way, can
- 23:56Speaker 1: you know, essentially step between pharmacies and PBMs and rein
- 24:02Speaker 1: and anti competitive behavior. Cms's initial interpretation, right, really wasn't
- 24:08Speaker 1: wasn't that? And so I think it's another example of
- 24:11Speaker 1: maybe maybe not regulatory capture, but the PBMs and prescription
- 24:15Speaker 1: drug plans and insurers really getting CMS to agree with
- 24:20Speaker 1: their view and legal interpretation of the non interference clause,
- 24:24Speaker 1: which is really draconian for providers for sure. A little
- 24:29Speaker 1: bit of a digression, but one of the things that
- 24:31Speaker 1: American Pharmacy Cooperatives submitted in terms of our comments was
- 24:36Speaker 1: sort of the angle of how CMS REGs can oftentimes
- 24:40Speaker 1: embolden some of these problematic practices, and we talked about
- 24:43Speaker 1: the safe harbor. One of the things that I think
- 24:45Speaker 1: doesn't get talked about enough is that federal law reads
- 24:49Speaker 1: to me really ambiguously. It says that beneficiaries in Part
- 24:53Speaker 1: D should get the benefit of negotiated prices in federal law,
- 24:58Speaker 1: and in federal law it concludes with the definition rebates, right,
- 25:04Speaker 1: And so essentially PBMs are able to deny Thenficieri's rebates
- 25:09Speaker 1: in Part D on a massive scale. In twenty twenty one,
- 25:12Speaker 1: we know through a MedPAC report that they denied beneficiar
- 25:14Speaker 1: is fifty billion dollars in discounts. Right, So senior is
- 25:19Speaker 1: overpaid fifty billion dollars in twenty twenty one for prescription drugs.
- 25:24Speaker 1: And they're able to do that because cms is definition
- 25:27Speaker 1: of negotiated price doesn't include drug manufacturer discounts. So they
- 25:32Speaker 1: just sort of exclude and based on stakeholder input, a
- 25:36Speaker 1: category where there's fifty billion dollars in discounts that aren't
- 25:40Speaker 1: being passed back to beneficiaries. And so you know, there's
- 25:44Speaker 1: sometimes there's so many different ways you can tackle this right, Like,
- 25:47Speaker 1: obviously there's potential for law change. There's the potential to
- 25:51Speaker 1: do it via the safe harbor, whether it's law or
- 25:53Speaker 1: regulatory which via Trump initially did following his executive order
- 25:58Speaker 1: in his first term. But it could also be as
- 26:00Speaker 1: simple was changing the definition of negotiated price, which CMS
- 26:04Speaker 1: absolutely has the power to do. They did it a
- 26:06Speaker 1: few years ago with regard to pharmacy discounts. So but
- 26:10Speaker 1: I was a big fan of big fan of your comments.
- 26:12Speaker 1: And again I thought it was just another example of
- 26:15Speaker 1: American economic liberties weighing in in a really smart way,
- 26:19Speaker 1: in an aggressive way, but with like well founded solutions.
- 26:23Speaker 1: So I thought, I thought, really very well done.
- 26:27Speaker 2: Well, the feeling is mutual. I really like how an
- 26:29Speaker 2: apcied comment you focused on, you know, where there's daylight
- 26:35Speaker 2: between the law and the regulations, and you know, getting
- 26:40Speaker 2: rid of anti competitive regulations might mean making sure that
- 26:44Speaker 2: the law is being enforced as it was written.
- 26:47Speaker 1: Yeah, it's with its spirit because saying right, we've got
- 26:49Speaker 1: any willing provider yet CMS has paved the way for
- 26:53Speaker 1: you know, preferred networks, which is again another another tool
- 26:56Speaker 1: that can be used to steer in a multiple of ways.
- 27:00Speaker 2: Yeah, and something that you know, kind of gives me
- 27:03Speaker 2: hope and forwarded to and doing this work is something
- 27:05Speaker 2: that my colleague Haiden Replay often says, which is like
- 27:09Speaker 2: public policy like the ones that you pointed out, the
- 27:11Speaker 2: CMS regulations, you'll help get us into this mess, but
- 27:15Speaker 2: it's also the solution. You know, Yes, smart policy making
- 27:18Speaker 2: can get us out of there's mession really improve a situation.
- 27:21Speaker 2: And I feel like it's it's exciting to like read
- 27:24Speaker 2: people's comments and see what where the new ideas for improvement?
- 27:30Speaker 1: Right, absolutely. And another thing, this is a little bit
- 27:33Speaker 1: of digression, but I mean you guys do a lot
- 27:35Speaker 1: of work in terms of trying to bring in stakeholders
- 27:38Speaker 1: and bounce around ideas and come up with policy solutions,
- 27:42Speaker 1: and I don't know that that happens enough, right, So
- 27:44Speaker 1: often we're all in our own bubble or our own vacuum.
- 27:47Speaker 1: Lord knows I am when it comes to you know
- 27:48Speaker 1: a lot of this stuff, right, it's easy to put
- 27:50Speaker 1: your head down and just be sort of operating from
- 27:54Speaker 1: our own perspectives. And I think you guys are also
- 27:56Speaker 1: great in terms of building coalitions to advance these policies.
- 28:02Speaker 2: Yeah, No, that's like one of my favorite parts of
- 28:04Speaker 2: their job is getting to talk to people and also
- 28:07Speaker 2: learning from experts. So like independent pharmacists have been such
- 28:13Speaker 2: leaders in this space and have really you know, the
- 28:15Speaker 2: PBM reforms that we're seeing today, I know have been
- 28:20Speaker 2: the product of years, decades even of work. And I
- 28:24Speaker 2: think a lot of other healthcare professionals. We're seeing physician
- 28:27Speaker 2: being united, We're seeing residents unionized, We're seeing other subsets
- 28:32Speaker 2: of healthcare professionals really want to I think are feeling
- 28:36Speaker 2: a lot of the anks and despair about where their
- 28:40Speaker 2: industry is headed, and have a lot to learn from
- 28:42Speaker 2: independent financists organizations that have been leaders in this space.
- 28:47Speaker 2: So you know, we often I don't think that my
- 28:50Speaker 2: colleges talk about alp is, you know, kind of leveraging
- 28:55Speaker 2: all that expertise and helping people connect who can learn
- 28:57Speaker 2: from each other. And we can learn from experts in
- 29:00Speaker 2: this space because you know, we aren't focused on any
- 29:03Speaker 2: one thing. We work in a lot of different areas,
- 29:06Speaker 2: so we really rely on the organizations that are the
- 29:11Speaker 2: subject experts to guide the work that we do.
- 29:14Speaker 1: Yeah, well it's very cool, and again, you guys have
- 29:17Speaker 1: built some some really strong coalitions and that's that's a
- 29:20Speaker 1: neat thing to see. You guys have also engaged, I
- 29:23Speaker 1: think in a really high end way with the FTC
- 29:26Speaker 1: in connection with the six p study. I don't want
- 29:28Speaker 1: to you know, extending, We got to get to the
- 29:29Speaker 1: congressional stuff too, but just real quick, your your thoughts
- 29:33Speaker 1: are a little summary of the work you all have
- 29:35Speaker 1: done with the FTC and connection with the six Pece study,
- 29:38Speaker 1: because you guys have done some great stuff there.
- 29:42Speaker 2: Yeah, I mean, the FTC has done really great work
- 29:44Speaker 2: in this space, and this kind of predates mind joining ALP.
- 29:47Speaker 2: But I know we the FTC had a huge role
- 29:51Speaker 2: to play and obviously ensuring why kets are competitive. And
- 29:57Speaker 2: I think with PBMs we have this ongo going study
- 30:00Speaker 2: that has already produced two really substantial reports that have
- 30:04Speaker 2: given us so much more information about how PBMs operate.
- 30:07Speaker 2: I think it's galvanized so much outrage, rightly so on
- 30:12Speaker 2: the Hill and in the public. We see such great
- 30:15Speaker 2: reporting in the New York Times and other outlets on this.
- 30:21Speaker 2: We now have a lawsuit against the Big three for
- 30:24Speaker 2: jacking up the price of insulin, which is you know,
- 30:26Speaker 2: obviously has very deadly consequences. You know, we would really like,
- 30:34Speaker 2: you know, more recently, what we've been advocating for is
- 30:37Speaker 2: that the FDC finished at study, you know, really aggressively
- 30:41Speaker 2: litigate its case against the Big Three, and we really
- 30:44Speaker 2: see this study and the lawsuit as templates for additional
- 30:48Speaker 2: future investigations into drug pricing. So, you know, we really
- 30:56Speaker 2: we're being supportive of the FTCs of investigation fear into
- 31:01Speaker 2: purchasing organizations and wholesale drug distributors and they are all
- 31:05Speaker 2: in diving up prices and also contributing to really constant
- 31:10Speaker 2: dangerous drug shortages. We would love to see them take
- 31:15Speaker 2: a similar approach to you know, publishing these really end
- 31:18Speaker 2: up studies and also suing the Big three and those
- 31:22Speaker 2: the GPO and wholesale markets, similar to how they'd taken
- 31:26Speaker 2: on the PBMs.
- 31:28Speaker 1: Yeah. Absolutely, And you know, I thought one of the
- 31:31Speaker 1: interesting things that you know, in connection with like the
- 31:33Speaker 1: DOJ suit on the insulin was based on Section five,
- 31:36Speaker 1: you know, the FTC Act Unfair Trade Practices of CO
- 31:40Speaker 1: which there's not a private right of action under that.
- 31:43Speaker 1: But look like insulin in the only place that's going
- 31:46Speaker 1: on right there's there's so many, so many different areas
- 31:50Speaker 1: that you know, prescription drugs, brand name drugs, where we
- 31:53Speaker 1: see those same rebate games and brand mandates when there's
- 31:56Speaker 1: lower cost generics, and you know, just just so many
- 32:00Speaker 1: of those practices. So okay, I do want to switch
- 32:05Speaker 1: here and talk a little bit about congressional action because
- 32:09Speaker 1: it's been I think just fascinating at the federal level.
- 32:13Speaker 1: We'll say and love you know again, we could have
- 32:16Speaker 1: you on again to talk about just the state stuff.
- 32:18Speaker 1: I mean, there's been so much activity at the state level,
- 32:22Speaker 1: but for years and years and years right in pharmacy
- 32:26Speaker 1: there there really hasn't been I would say, super super
- 32:30Speaker 1: aggressive PBM reform, right, like like you've seen at the
- 32:33Speaker 1: state levels, certainly where there's just you know, you've seen
- 32:36Speaker 1: Arkansas introduced first in the nation bills, and West Virginia
- 32:41Speaker 1: and Kentucky, Georgia, Tennessee. Right, there's been There's been a
- 32:46Speaker 1: whole and I don't leave out the north, right New
- 32:48Speaker 1: York has done some really big stuff you've just you've
- 32:51Speaker 1: just seen in Oklahoma never gets enough credit. I don't
- 32:53Speaker 1: think Oklahoma always passes some really big, interesting PBM stuff.
- 32:58Speaker 1: But so so we really haven't seen the federal initiatives
- 33:03Speaker 1: really match that pace and and oftentimes, you know, some
- 33:07Speaker 1: of the federal initiatives are following what states have done
- 33:10Speaker 1: several years ago in many many ways. Right, So there
- 33:14Speaker 1: has been some momentum, you know regarding like a potential
- 33:17Speaker 1: by bipartisan package, you know that seemingly both chambers have
- 33:23Speaker 1: agreed on. And one of the things that's in there
- 33:25Speaker 1: that we like a lot is that, you know, it's
- 33:26Speaker 1: certainly the Medicaid Managed Care reform and basically taking away
- 33:32Speaker 1: the ability of PBMs to set you know, drug prices
- 33:35Speaker 1: and Medicaid managed care prohibits spread pricing, you know, pay
- 33:39Speaker 1: based on Nate Act plus a fair dispensing fee. But
- 33:42Speaker 1: but and there's some you know, some transparency provisions in
- 33:45Speaker 1: there as well. But I would say other than that,
- 33:47Speaker 1: there's not been a lot of you know, a lot
- 33:49Speaker 1: of you know, really aggressive dilutions until the last few years.
- 33:55Speaker 1: And you guys, I think, have really jumped out and
- 33:58Speaker 1: supported some of this legislation even when even when sometimes
- 34:03Speaker 1: others have been hesitant to because you know, maybe they know,
- 34:06Speaker 1: hey it's too aggressive, or hey we have to move
- 34:09Speaker 1: at you know, sort of the slower pace. But you know,
- 34:12Speaker 1: one of the one of the big things was the
- 34:14Speaker 1: Patient Perform Monopolies Act, right, And you guys, we were really,
- 34:18Speaker 1: I think, I think loud enthusiastic proponents of that concept
- 34:22Speaker 1: and continue to be, you know, for listeners who may
- 34:25Speaker 1: not know, can you talk a little bit about what
- 34:26Speaker 1: that does and why you all got behind it the
- 34:30Speaker 1: way that you did.
- 34:32Speaker 2: Yeah, No, I would love to talk about the Patient's
- 34:34Speaker 2: Perform Monopoly Act. So this is bipothoge in legislation introduced
- 34:38Speaker 2: last session by Senator Elizabeth Ie and Josh Holly and
- 34:42Speaker 2: the Senate and Representative to Glockenclash and Diana Harshbarga in
- 34:46Speaker 2: the House, biprithogen bicameral. And you know, a lot of
- 34:51Speaker 2: times legislation is really confusing. This I think is really
- 34:54Speaker 2: easy to explain. This bill would require insurance companies and
- 34:59Speaker 2: PBMs own pharmacies to divest their pharmacy businesses within three years.
- 35:06Speaker 2: You know, we really see this as critical to this
- 35:09Speaker 2: fight to break up big medicine. All three of the
- 35:13Speaker 2: largest PBMs are owned by the largest intros. They also
- 35:17Speaker 2: also own pharmacies, mail order pharmacy, specialty pharmacies, and that
- 35:22Speaker 2: vertically integrated structure creates all sorts of perverse incentives to
- 35:26Speaker 2: drive prices up to really really gouge independent pharmacy reimburse
- 35:33Speaker 2: them less and no costs. It's driving independent pharmacies out
- 35:38Speaker 2: in business. They're overpaying their own pharmacy subsidiaries in like
- 35:45Speaker 2: crazy markups. The second XISY support sure that the markups
- 35:48Speaker 2: could be the highest seven and thirty three percent on
- 35:52Speaker 2: a rigs for certain drugs, and I think that number
- 35:55Speaker 2: is like bananas high and at once.
- 35:58Speaker 1: And through it.
- 36:00Speaker 2: But this bill would say if you want to be
- 36:03Speaker 2: a PBM, you can't also own pharmacies. There's so many
- 36:06Speaker 2: conflicts of interest in hand to their common ownership and
- 36:10Speaker 2: it shouldn't be allowed. And I think when it would
- 36:12Speaker 2: introduce last session it was seen as you know, maybe
- 36:17Speaker 2: not feasible in the short term. And incredibly, Arkansas has
- 36:22Speaker 2: just passed its own equivalent version of the bill at
- 36:25Speaker 2: the state level. And as part of that effort, to
- 36:29Speaker 2: Arkansas Attorney General and I think thirty eight other state
- 36:33Speaker 2: and territory ags wrote a letter to Congress saying, you
- 36:36Speaker 2: guys should do the same thing. You should pass legislation
- 36:39Speaker 2: like this. So I think we're seeing really widespread five
- 36:42Speaker 2: partisan support for this type of reform. And I know
- 36:46Speaker 2: we're here to talk about PBM reform, but at AEOP
- 36:49Speaker 2: we're really excited about what this bill in particular means
- 36:53Speaker 2: for additional structural separation also in healthcare, because it's obviously
- 36:58Speaker 2: PBM's owning finacy is it a huge problem, but so
- 37:01Speaker 2: is insurance companies owning the different practices and wholesale good
- 37:05Speaker 2: distributors owning oncology clinics. You know, those are also big
- 37:08Speaker 2: problems that we want to see addressed. And this is
- 37:11Speaker 2: really I think, straightforward legislation that would help.
- 37:14Speaker 1: It is right, it's simple. And I'll tell you something
- 37:19Speaker 1: that excited me is again a that you're seeing just
- 37:23Speaker 1: aggressive federal reform because historically we haven't seen that in
- 37:26Speaker 1: the PBM space, right And what I don't hold me
- 37:30Speaker 1: my feet to the fire on this, but almost always
- 37:33Speaker 1: federal bills are sort of following something that's happened in states.
- 37:37Speaker 1: And here, you know, this is a federal policy that
- 37:40Speaker 1: was presented and what happens Arkansas, by God, picks it
- 37:43Speaker 1: up and runs with it. And you know, there are
- 37:45Speaker 1: some folks who thought, hey, maybe this is just a
- 37:47Speaker 1: messaging bill, Maybe this is just really setting a statement.
- 37:50Speaker 1: And I can't speak for them. I don't think the
- 37:52Speaker 1: bill sponsors looked at it that way as all right,
- 37:55Speaker 1: and I'll tell you what, it wasn't a messaging bill
- 37:57Speaker 1: in Arkansas because it's the law. And you know, Governor
- 38:00Speaker 1: Or Sara Huckabee Sanders has just been a steadfast champion
- 38:03Speaker 1: of this and not only did she sign it into law, right,
- 38:06Speaker 1: but I mean she has been a vocal champion on
- 38:09Speaker 1: ending anti competitive PBM practices, and so it's it's just
- 38:13Speaker 1: so exciting to see a state sort of again there
- 38:17Speaker 1: was a federal bill and then we see states sort
- 38:21Speaker 1: of looking at that policy and it's shaping the direction
- 38:24Speaker 1: of where their policy goes. And if they didn't, you know,
- 38:29Speaker 1: not only did they introduce it, they passed it and it's,
- 38:32Speaker 1: you know, the law of the land in Arkansas.
- 38:35Speaker 2: Yeah. Absolutely, And I think it's so great about this
- 38:38Speaker 2: bill sponsored in Congress. I think they really committed to
- 38:40Speaker 2: this work. You know, big Talking Clash and Diana Huschberger
- 38:44Speaker 2: are constantly talking about CBM. I think One and Holly
- 38:48Speaker 2: have done really interesting work together on aggression corporate power
- 38:53Speaker 2: in trying to rein that in And I also you know,
- 38:58Speaker 2: when we were talking about Congress, it seems starting to
- 39:03Speaker 2: really consider these more structural reforms. I sit and listen
- 39:08Speaker 2: to all of the hearings that they have on PBM's
- 39:11Speaker 2: and there's been a lot recently and increasingly you hear
- 39:14Speaker 2: members on both sides ties to the Aisle basically expressed
- 39:17Speaker 2: frustration that they're in yet another hearing about PBM apartment
- 39:21Speaker 2: they have yet to pass. You know, I think that
- 39:24Speaker 2: kind of frustration might be a good motivator for getting
- 39:29Speaker 2: some of these more significant reforms.
- 39:32Speaker 1: Absolutely, and it's also nice to see that that you've
- 39:36Speaker 1: got sort of new new champions and other champions emerging,
- 39:41Speaker 1: and a lot of these folks, I don't want to
- 39:42Speaker 1: say a lot of these folks have been doing you know,
- 39:44Speaker 1: good work for a long time on the issue. But
- 39:47Speaker 1: you know, as recently as you know, eight years ago,
- 39:51Speaker 1: it seemed in a way right that they obviously represented
- 39:54Speaker 1: Buddy Carter, who's a pharmacist, was was ringing, ringing the bell,
- 39:58Speaker 1: maybe the loudest you had. Doug Collins represented then Representative
- 40:03Speaker 1: Doug Collins, who was just one of the original champions
- 40:07Speaker 1: for PBM reform at the federal level. But I mean
- 40:10Speaker 1: we're at a point now where I mean there are
- 40:12Speaker 1: there are there are a lot of folks who were
- 40:15Speaker 1: fighting really really hard to rein in anti competitive PBM
- 40:19Speaker 1: practices and also to bring just fairness to the market,
- 40:23Speaker 1: and you know, in the House and the Senate, and
- 40:26Speaker 1: so it's really neat. I mean there were I don't
- 40:28Speaker 1: even know how many bills by the end of twenty
- 40:30Speaker 1: twenty four. How many bills do you think we're touching
- 40:34Speaker 1: PBMs and drug pricing in Congress. I don't mean to
- 40:39Speaker 1: put you on the spot over sixty seventy, I mean really.
- 40:44Speaker 2: Like scored and I think you see a really wide
- 40:47Speaker 2: range of kind of aggressiveness in those bills. You know,
- 40:50Speaker 2: some are the very incremental and then others are taking
- 40:52Speaker 2: big swings, but.
- 40:54Speaker 1: Big swings Parmasist fight back then you guys were again
- 40:59Speaker 1: there were there were some some folks out there who
- 41:00Speaker 1: are hesitant to get behind that out of the gate,
- 41:03Speaker 1: it ended up getting fifty six co sponsors, and you
- 41:06Speaker 1: all did a lot of work on it, like that
- 41:09Speaker 1: was one that you all liked. And again we've talked
- 41:12Speaker 1: about sort of smaller change versus sweeping change, and that bill,
- 41:16Speaker 1: you know, did look to take away the ability for
- 41:18Speaker 1: PBMs to set drug prices, take away their ability to steer,
- 41:22Speaker 1: take away their ability to restrict access via preferred networks.
- 41:26Speaker 1: But talk to us a little bit about why you
- 41:28Speaker 1: got behind that bill as strongly as you did.
- 41:32Speaker 2: Yeah, I mean again, we want to see these markets restructured,
- 41:35Speaker 2: and I think the Pharmacy S Fight Back Act, you know,
- 41:39Speaker 2: it really will restore the financial viability of the independent
- 41:44Speaker 2: pharmacy model by shutting these baseline reimbursement rates and federal
- 41:51Speaker 2: healthcare programs, which of course are huge, huge populations. And
- 41:56Speaker 2: I think when you know, people who maybe aren't in
- 42:00Speaker 2: the pharmacy world here that a PBM can be in
- 42:03Speaker 2: verse a pharmacy below cost like, of course, that doesn't
- 42:06Speaker 2: make any business sense. That's why we have pharmacy deserts.
- 42:10Speaker 2: That's why patients are struggling to get the type of
- 42:13Speaker 2: in person care that they want and deserve and expect.
- 42:18Speaker 2: So I think this bill, you know, really addresses like
- 42:22Speaker 2: a clear problem, which is PBMs using their market power
- 42:25Speaker 2: to not you know, under reimburse their competitors who are
- 42:33Speaker 2: independent pharmacies, and it would mandate that they pay them
- 42:37Speaker 2: a bigger competitive price again like simple, and I think
- 42:44Speaker 2: we've seen, you know, we've seen the viability of this
- 42:49Speaker 2: type of intervention in states that have carved out pharmacy
- 42:53Speaker 2: benefits from their Medicaid managed care program. Like, we know
- 42:57Speaker 2: that this is effective, we know that it works, we
- 42:59Speaker 2: know that it's shape money, we know that it helped
- 43:01Speaker 2: independent pharmacy stay and business. So it really is, you know,
- 43:05Speaker 2: a test good solution.
- 43:07Speaker 1: So to that point, I know we're running out of time,
- 43:10Speaker 1: but you've touched on this a few times, right, Like,
- 43:12Speaker 1: we we know these things. We've seen massive markups, right,
- 43:16Speaker 1: the FTCs uncovered them. We worked on a white paper
- 43:19Speaker 1: looking at cutter employee health plan and we found a
- 43:22Speaker 1: multiple sclerosis drug marked up forty seven percent, right, Like
- 43:26Speaker 1: just just craziness. But for years and years, you know,
- 43:30Speaker 1: PBMs and insurers have literally sold to clients, right, employer groups,
- 43:36Speaker 1: but also to governmental entities and really legislators sort of
- 43:40Speaker 1: this this narrative of hey, you know, steering saves money
- 43:44Speaker 1: and our pharmacies are lower cost, and it seems like
- 43:47Speaker 1: under every rock you look, the evidence runs counter to that.
- 43:51Speaker 1: And then and then to your point, I think you know,
- 43:56Speaker 1: as you see more and more states implement things and
- 43:58Speaker 1: you see more and more evidence of savings doing that. Right,
- 44:02Speaker 1: It's like that narrative doesn't doesn't fly anymore. Right, this,
- 44:07Speaker 1: this the vertical integrations saves money and and our vertically
- 44:11Speaker 1: integrated pharmacies we treat in a certain way, like it
- 44:14Speaker 1: just it doesn't seem to fly anymore. Would like your
- 44:16Speaker 1: opinion on this, And this is a little off the cuff,
- 44:18Speaker 1: not looking for a comprehensive answer, But despite all of
- 44:21Speaker 1: the evidence, right, the evidence of state reforms lowering costs,
- 44:25Speaker 1: the evidence of like massive markups, that three axis is uncovered,
- 44:29Speaker 1: or the FTC has uncovered, or things we've seen in states,
- 44:35Speaker 1: employers still very much sort of buy these long time
- 44:40Speaker 1: presumptions that PBMs have asserted. And also some you know,
- 44:44Speaker 1: some agency heads at the state and federal level, and
- 44:46Speaker 1: I would even argue some of the Congressional Budget Office
- 44:49Speaker 1: folks right accept these presumptions that sort of the status
- 44:54Speaker 1: quo is working. And I get change is hard, and
- 44:57Speaker 1: sometimes that's a compelling reason enough, But do you have
- 45:00Speaker 1: any thoughts on how you know how to sort of
- 45:05Speaker 1: open the eyes of folks in the commercial market or
- 45:09Speaker 1: some of these agencies at the state or federal level.
- 45:12Speaker 1: Any thoughts, because to your point, I mean like you're
- 45:15Speaker 1: saying it like it's a poor gong conclusion. These things
- 45:17Speaker 1: save money and these PBM practices raise costs, but there's
- 45:21Speaker 1: a lot of folks who still buy the opposite presumption.
- 45:25Speaker 2: Yeah, that's such a good question and something we've been
- 45:28Speaker 2: thinking about a lot. You know, we were talking earlier
- 45:30Speaker 2: about coalition building, and we think it's really important that
- 45:34Speaker 2: that coalition includes employers, business owners, you know, state Medicaid programs,
- 45:42Speaker 2: state employee benefit plans. I think business owners and employers
- 45:50Speaker 2: their voice have a lot of weight with elected officials,
- 45:53Speaker 2: and I you know, in talking to businesses, I do
- 45:57Speaker 2: think that there is a lot of fush stuation with
- 46:02Speaker 2: the current employee health plan environment. Maybe they don't have
- 46:09Speaker 2: the wherewithal to try to change it, maybe they don't
- 46:13Speaker 2: feel like they are expert enough in the healthcare industry
- 46:18Speaker 2: to pursue it further. But I don't think and there's
- 46:22Speaker 2: lots of pulling and studies that show that employers are
- 46:26Speaker 2: not happy with you know, their health plan costs rising
- 46:29Speaker 2: ten percent EU of the year, largely driven by prescription
- 46:33Speaker 2: drug costs that are jacked up by pdms, and I think,
- 46:37Speaker 2: you know, bringing them on board and building on, you know,
- 46:42Speaker 2: building their awareness of the problem. I think independent Primacies
- 46:46Speaker 2: and APCI and other organizations like yours have done such
- 46:49Speaker 2: a public service by educating the public about what PBMs
- 46:54Speaker 2: are and why they're problematic and how they hurt not
- 46:57Speaker 2: just fun issues but also patients, you know, leveraging that
- 47:01Speaker 2: greater public awareness to bring employers and business people into
- 47:06Speaker 2: the fold, bring shape policy makers into the fold, because
- 47:10Speaker 2: you know, I I don't have evidence to point you,
- 47:14Speaker 2: you know, right here in this moment, but I don't
- 47:16Speaker 2: think that they're satisfied with the service.
- 47:21Speaker 1: Absolutely love it, love it so and I know we're
- 47:25Speaker 1: about out of time here, so have to wrap up
- 47:27Speaker 1: when we talk about sort of magnifying messaging and magnifying voices,
- 47:32Speaker 1: and you know, I sort of started this with talking
- 47:35Speaker 1: about how we tend to speak in echo chambers. You know, you,
- 47:40Speaker 1: I think your voice and as well as American Economic
- 47:43Speaker 1: Liberties voice right like you guys are really really smart
- 47:46Speaker 1: voices on this issue and would certainly encourage all the
- 47:51Speaker 1: pharmacists and healthcare policy people that are listening to this
- 47:54Speaker 1: to follow your work and what you are doing via
- 47:57Speaker 1: your website. How how can pharmacists and healthcare policy people
- 48:02Speaker 1: at the state and federal level that listen to this podcast,
- 48:05Speaker 1: how can they follow the work that you're doing and
- 48:07Speaker 1: American Economic Liberties is doing.
- 48:11Speaker 2: Yes, well, an easy way to do that is to
- 48:13Speaker 2: go to a Breakup Big Medicine website, which is Breakupbig
- 48:17Speaker 2: Medicine dot com and that's really a home for a
- 48:20Speaker 2: healthcare policy work. You can sign up there to get
- 48:23Speaker 2: regular updates on policy developments. And you know, we are
- 48:26Speaker 2: serious when we say that we want to hear from
- 48:29Speaker 2: people who are signed up there. If you're a policy maker,
- 48:32Speaker 2: if you're a farmercist, if you are just obsessed with
- 48:36Speaker 2: how our healthcare system is broken and have ideas like
- 48:39Speaker 2: please reach out, I would love to hear more from you.
- 48:44Speaker 2: And you can get all of that at Breakupbig Medicine
- 48:47Speaker 2: dot com.
- 48:48Speaker 1: Awesome. And then do you have like an X account
- 48:51Speaker 1: or any other social media accounts where folks can follow you?
- 48:55Speaker 2: Yes, we do. We are on X. Let me make
- 48:58Speaker 2: sure I'm giving all the right handle. It is at
- 49:03Speaker 2: econ Liberty's. We can just search American Economic libertyes on
- 49:07Speaker 2: x r uh Economic Liberty's website is Economic Liberties dot
- 49:12Speaker 2: us and yeah, we would love, uh, we would love
- 49:17Speaker 2: to be the one more about us and to reach out.
- 49:20Speaker 1: That's great and I would encourage everybody to follow you. Again,
- 49:22Speaker 1: Like in my opinion, you all are doing some of
- 49:24Speaker 1: the smartest, most aggressive work that's that's being done. And
- 49:28Speaker 1: so thank you so much for joining today. Thank you
- 49:31Speaker 1: for all the work that you're doing in general right
- 49:35Speaker 1: but particularly with regard to PBM reform and PBM anti
- 49:39Speaker 1: competitive practices as well as also a voice for treating
- 49:43Speaker 1: independent pharmacies fairly in this and you know, in this
- 49:47Speaker 1: sort of crazy drug pricing system. So I can't thank
- 49:50Speaker 1: you enough. I want to have you back on so
- 49:52Speaker 1: we can talk more about state stuff at some point soon.
- 49:55Speaker 1: But just thank you so much for being here today.
- 49:59Speaker 2: Oh, thank you much, Beg, and congratulations on taking over
- 50:02Speaker 2: the podcast.
- 50:03Speaker 5: Thank you, Hey, We thank you listeners for listening to
- 50:06Speaker 5: the PBM Reform Podcast brought to you by a p
- 50:11Speaker 5: c I. You can learn more about a p c
- 50:13Speaker 5: I by going to a p c I net dot com.
- 50:16Speaker 5: Once again, that's a p c I net dot com.
- 50:21Speaker 5: Thank you, Greg, it's been great to talk with you
- 50:23Speaker 5: and listen to you and Emma discuss the importance of
- 50:26Speaker 5: PBM reform and how we can all work together to
- 50:31Speaker 5: make up a better system. That's that's in our midst today.
- 50:35Speaker 5: It has to get better. We all want it to
- 50:37Speaker 5: definitely get better. And I'm a half fast full kind
- 50:39Speaker 5: of guy. I think it is getting better. And we
- 50:41Speaker 5: can't wait to the next episode of the PBM Reform
- 50:45Speaker 5: Podcast and we'll talk with you soon.